Charles River Laboratories

Phase A — Understand the business

Lens 1 · Company Overview

Charles River is the infrastructure layer of early-stage drug development — "the backbone of discovery." It sells the picks-and-shovels that pharma and biotech need before a molecule ever reaches a human trial, and it does so across three reportable segments:

• DSA — Discovery & Safety Assessment (~60% of revenue). The crown jewel. Outsourced GLP and non-GLP toxicology, safety pharmacology, bioanalysis, and discovery services — the regulated animal and in-vitro studies an IND filing requires. FY2025 DSA revenue $2,402.9M, ~60% of the $4,015.4M total; Q1 2026 DSA $596.9M.
• RMS — Research Models & Services (~21%). The original franchise (founded 1947): commercial breeding and sale of small research models (rodents) and supply of large models (NHPs), plus colony management (Insourcing Solutions / CRADL vivarium space), genetically engineered models (GEMS), diagnostics (RADS), and Cell Solutions. FY2025 RMS $846.1M; Q1 2026 $208.4M.
• Manufacturing Solutions (~19%). Microbial Solutions (the Endosafe endotoxin lot-release testing razor-and-blade franchise), Biologics Testing, and a CDMO. FY2025 $766.4M; Q1 2026 $190.5M.

Customers: the entire pharma/biotech R&D complex — big pharma, mid-tier, biotech, plus academic and government. Concentration is a genuine strength: "during 2025, no single client accounted for more than 4% of our total revenue and no single client accounted for more than 8% of the revenue of any of our three business segments". Contract structure is mostly fee-for-service recognised over time (cost-to-cost or right-to-invoice); ~60% of total revenue is DSA recognised over time. This is not recurring SaaS — it is project-based services exposed to study cancellations and biotech funding cycles. ~19,700 employees (incl. ~2,400 advanced-degree scientists) as of Dec 27, 2025. HQ Wilmington, MA; NYSE: CRL; ~48.2M shares out (Apr 2026).

The structural pitch: drug discovery takes 10–15 years, ~$2.6B, and screens 10,000–15,000 molecules per FDA approval; outsourcing that to CRL is cheaper and faster than building it in-house. CRL is the toll bridge across that spend.

Lens 2 · Supply Chain

Map upstream → CRL → end customer:

Upstream inputs into CRL:

• Non-human primates (NHPs / cynomolgus macaques) — the single most important, most fragile, and most litigated input. Used in DSA for large-molecule (biologics/mAb) safety studies and supplied via RMS. Historically sourced from Asia (Cambodia, China, Mauritius). This is the chokepoint of the entire business. In Jan 2026 CRL moved to own it: it acquired K.F. Cambodia Ltd, a leading Cambodian NHP supplier, for $507.3M ($335.0M at close + $172.3M deferred; $105.0M still payable at Q1-end) to "diversify and secure its NHP supply chain" and ensure animals are "purpose-bred". Vertical integration as a defensive moat — and a regulatory hedge.
• Small research models (rodents) — bred in-house globally; CRL is the producer, not a buyer. This is the low-controversy, high-share core of RMS.
• Lab consumables, reagents, scientific labour (the ~2,400 PhDs/DVMs/MDs), and global vivarium/GLP-lab real estate (PP&E $1,510M net at Q1 2026).

CRL → end customer:

• DSA studies, research models, Endosafe testing systems/cartridges, and biologics/CDMO output flow to pharma & biotech R&D and QC departments. Endosafe is the embedded razor-blade — once a manufacturer validates it into a lot-release SOP, it recurs.

Named stakeholders / chokepoints:

• Chokepoint #1 — NHP supply. Single-source-ish, geographically concentrated, and the subject of a US DOJ investigation and securities litigation (Lens 10). The K.F. Cambodia deal addresses supply security but raises supply concentration in Cambodia precisely as US import scrutiny of Cambodian macaques is acute.
• Chokepoint #2 — GLP capacity. Safety studies require accredited facilities and skilled staff; capacity is hard to flex down (high fixed cost) — which is exactly why margins crater when DSA volumes fall.
• Partners: CRL is integrating into AI-discovery distribution — June 2026 it joined Lilly's TuneLab (Lilly Catalyze360) to provide nonclinical testing to TuneLab biotechs. Names along the chain matter here: CRL wants to be the default safety-testing layer underneath the AI-drug-discovery platforms.

This lens passes the "names or it didn't happen" test: K.F. Cambodia, Endosafe, Lilly TuneLab, CRADL.

Lens 3 · Competitive Advantages (moats)

Real, durable moats — but on a shrinking base:

1. Scale + regulatory entrenchment in safety assessment. CRL is the largest non-clinical safety-testing provider globally; GLP toxicology is a trust-and-track-record business where switching is risky for a sponsor mid-program. High.
2. NHP supply control. Post-K.F. Cambodia, CRL owns a scarce, regulated input rivals must buy. In a world where NHPs stay necessary, this is a widening moat; in a world where the FDA phases out NHP studies (Lens 10/13), it is a $507M stranded asset. The moat and the bear thesis are the same fact.
3. Endosafe razor-and-blade (Manufacturing). FDA-approved endotoxin lot-release testing embedded in clients' QC SOPs — genuine switching costs and recurring cartridge pull-through. The highest-quality micro-franchise in the company.
4. Breadth / one-stop-shop. Discovery → safety → manufacturing QC under one roof lets sponsors compress timelines; ~80% of FDA-approved drugs historically touched CRL somewhere (company positioning; treat as marketing, label ).
5. Low customer concentration (<4% any client) — pricing resilience, no single-customer cliff.

Bargaining power: strong over small/mid biotech (who can't replicate GLP capacity); weaker over large pharma (who can insource and negotiate hard, and who are CRL's own NAMs competitors via internal labs). Net: CRL needs big pharma slightly more than big pharma needs CRL, but the long tail of biotech needs CRL badly.

Ground truth: positioning.md / bottlenecks.md are missing on the shelf (KB genomics wiki not populated for this name) — moats above are derived from the 10-K business section + web, not a compiled commercial layer.

Lens 4 · Segments

FY2025 vs FY2024:

What this says: consolidated revenue has now declined two years running ($4,129M FY23 → $4,050M FY24 → $4,015M FY25) — a genuine CRO downcycle driven by biotech funding contraction and big-pharma R&D rationalisation. GAAP operating income collapsed 88.9% to a 0.6% margin — but that is impairment noise: RMS op. income fell 61% and Manufacturing swung to a −$184.3M loss, both gutted by intangible-asset impairment (a ~$210M impairment line appears in the FY2025 P&L) and biological-asset/step-up amortisation. DSA — 60% of revenue — held its margin near 18%, which is what actually matters.

Q1 2026 vs Q1 2025:

Geography FY2025: US $2,141.8M (53%), Europe $1,102.7M (27%), Canada $501.0M (12%), Asia-Pac $205.0M (5%), other $64.9M. Trend read: the worst of the DSA deceleration looks to be flattening (Q1 DSA back to +0.7%, Manufacturing accelerating +6.8% as the impairment drag laps), but unallocated-corporate cost is rising (−$80.6M in Q1, up from −$54.3M) — a watch item on the "margin expansion" guide.

---

Phase B — Measure performance

Lens 5 · Earnings Result (Q1 2026, ended 2026-03-28)

The headline GAAP loss is misleading; the operating story is "stabilising."

• Revenue $995.8M, +1.2% reported YoY (organic −1.5% per management; the difference is M&A + FX). Service $798.2M + product $197.7M. Beat consensus (~$978M).
• GAAP operating income $119.9M (12.0% margin) — up from $74.7M, but flattered by amortisation falling to $15.3M from $65.3M (intangibles winding down).
• GAAP net loss $(14.8M), $(0.30)/sh — driven entirely by a $(124.1M) "Other expense, net" (vs −$12.2M PY), which on the cash-flow statement maps to venture-capital / strategic-equity investment markdowns and long-lived asset impairments ($15.9M). This is a non-operating mark, not a demand signal.
• Non-GAAP EPS $2.06, beat $1.94, but −12% YoY. The −12% is the real operating reality: pricing/mix and the cost base still under pressure.
• Guidance REAFFIRMED (not raised): FY2026 organic revenue −0.5% to −1.5%, non-GAAP EPS $10.80–$11.30 (+5–10% vs FY2025), with 120–150 bps of margin expansion weighted to H2; reported revenue cut ~50 bps to −4.0% to −5.5% on a stronger US dollar.
• Balance-sheet flags (the real story of the quarter):
• Operating cash flow collapsed to $41.1M from $171.7M (−76%), entirely from a $(106.1M) working-capital build — chiefly inventories up $299.1M → $359.7M. Inventory outrunning flat revenue is a yellow flag (Lens 10).
• Debt levered up to fund M&A: revolver drawn $616.5M → $1,165.1M; total debt & finance leases $2,152M → $2,683M (+$531M); cash $191.8M (of which only $1.4M sits in US entities — a structural quirk). Net debt ≈ $2.49B.
• Goodwill $2,764M → $3,040M and "Other assets" jumped $293M → $826M (the K.F. Cambodia biological assets / deferred consideration mechanics).
• Still bought back $208.3M of stock in the quarter — buying shares while drawing the revolver to buy a monkey farm. Capital allocation is now explicitly Elliott-shaped (Lens 9).
• Market reaction: stock has re-rated up through 2026 (to ~$213, near the top of a $144–$229 52-wk range) on the "trough is in + capital return + new CEO" narrative — i.e., the market has already priced the stabilisation.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (transcripts/ empty); sentiment is from the Q1 2026 call coverage and the strategic-review arc.

Tone shift over the cycle: the 2023–2024 calls were defensive/apologetic — biotech-funding collapse, DSA bookings and net-book-to-bill under pressure, NHP-supply and DOJ overhang, guidance cuts. Through 2025 the language pivoted, under Elliott pressure, from "growth at any cost" to operational efficiency, footprint optimisation, and capital return. The Q1 2026 call is cautiously constructive: management reaffirmed guidance, leaned on margin expansion (120–150 bps), restructuring savings, and demand stabilisation in DSA, and framed the K.F. Cambodia deal and the Lilly TuneLab/AI partnerships as offence. Recurring phrases: "stabilisation," "margin expansion," "disciplined capital allocation," "strategic review." Things they stopped saying: aggressive M&A-led growth targets; the long-run organic growth algorithm. Net: a company managing a cyclical trough for cash and margin, not selling a growth story.

Lens 7 · Comps

Peer set = clinical/preclinical CRO + lab-services complex:

. 5-yr avg ROE and dividend yield: n/a (CRL pays no dividend; ROE distorted by the FY2025 impairment-driven GAAP loss — do not fabricate a clean figure).

Read: CRL at ~18x fwd P/E / ~11.4x EV/EBITDA sits mid-pack — cheaper than ICON/Medpace, in line with IQVIA, slightly below Labcorp on EBITDA. It is not statistically cheap given two years of revenue decline and a structurally-threatened core (DSA/NHP). The multiple already embeds a 2026 stabilisation; you are not being paid much for the regulatory tail risk. Medpace's ~29x EBITDA is the "pure clinical grower" premium CRL structurally cannot earn.

Lens 8 · Stock-Price Catalysts (what moves CRL >5%)

Pattern over the cycle:

• Guidance revisions dominate. The Feb-2023 disclosure tied to NHP-import practices (DOJ subpoena / Cambodian macaque seizure) and subsequent guidance cuts drove the stock from ~$250+ down toward the $140s — the single biggest drawdown. CRL trades on forward organic-growth and margin guidance, not the current print.
• Activist / governance events move it up: Elliott's stake and the May-2025 Cooperation Agreement + strategic review re-rated the name; the Jan-2026 CEO-succession announcement (Girshick) sent the stock +9.1%; a +5.2% day to $212.71 on Jun 25, 2026.
• FDA/NAMs headlines (animal-testing phase-out) are an emerging swing factor — ambiguous: bearish for DSA-NHP long-term, but CRL has spun some headlines as opportunity (AMAP, alternative methods).
• Earnings beats with reaffirmed guidance produce muted-to-positive reactions now that expectations are reset low.

Conclusion: the market reacts to (1) organic-growth/margin guidance and (2) capital-allocation & governance catalysts far more than to any single customer or the GAAP line. That makes the FY2026 margin-expansion delivery and any strategic-review outcome (asset sales? portfolio reshaping?) the dominant near-term catalysts.

---

Phase C — Judge people & books

Lens 9 · Management

A founder-era company in the middle of a generational handover, on activist terms.

1. Track record (outgoing) — James C. Foster. ~50 years at CRL, 30+ as CEO; built it from a research-models supplier into a ~$4B global preclinical platform and an S&P 500 member. Genuine empire-builder — but the late-cycle record is mixed: aggressive debt-funded M&A (the source of the goodwill now being impaired), an NHP-sourcing scandal on his watch, and a stock round-trip from ~$450 (2021 peak) to the $140s. Elliott's arrival is the market's verdict on the last few years of capital allocation.
2. Incoming — Birgit Girshick, CEO (named Jan 2026, effective May 2026). Long-time insider (decades at CRL, prior COO/EVP running large parts of RMS and Manufacturing) — continuity, not a clean-sheet outsider. Stock rose +9.1% on the appointment (the Street liked an operator over a disruptor). Martin Mackay (ex-Lead Independent Director) became Board Chair at the 2026 AGM; Foster stays as a non-executive director.
3. Capital-allocation history → now Elliott-governed. The pivot is explicit: away from "growth at any cost" M&A toward operational efficiency + capital return. Concrete moves: a new $1.0B buyback authorised Oct 2025 (replacing one with $549M left); $350M repurchased in FY2025 + $208.3M in Q1 2026; board refresh under the May-2025 Cooperation Agreement. Yet they also spent $507M on K.F. Cambodia and drew the revolver to $1.16B — so this is "return capital and make one big defensive acquisition," a slightly conflicted signal.
4. Red flags. The securities class action names Foster (CEO) and two former CFOs (David Smith, Flavia Pease) over NHP-import disclosures (Lens 10) — a governance black mark. CFO turnover (two former CFOs named) is itself a yellow flag. No evidence of related-party self-dealing or promotional stock-pumping.
5. Archetype: transitioning from founder-operator (Foster) to professional insider-operator (Girshick) under activist supervision (Elliott). For a mature, cyclical, cash-generative business at a trough, that is arguably the right archetype — the value-creation lever here is efficiency and capital return, not visionary reinvention.

insider-transactions.csv not present on the shelf — insider-ownership quantification is n/a.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst on the two filings:

• Inventory outrunning revenue (cash-quality flag). Inventories +$60.6M QoQ ($299.1M → $359.7M) against flat revenue, the main driver of the $(106.1M) working-capital drain and the OCF collapse to $41.1M. Some is the K.F. Cambodia biological-asset consolidation and inventory step-up, but it warrants tracking — DSO/inventory days rising on flat demand is the classic CRO-trough tell.
• GAAP earnings quality / impairments. FY2025 carried a ~$210M intangible-asset impairment plus elevated amortisation that turned RMS and Manufacturing GAAP-loss-making; Q1 2026 booked a $(124.1M) "Other expense" (VC/strategic-equity markdowns) and $15.9M long-lived impairment. None of this is fraud — it is the cost of the prior M&A binge washing through — but it means GAAP is uninformative; the entire thesis runs on non-GAAP, which (a) adds back heavy stock-based comp and (b) excludes the very impairments that prove past capital was destroyed. Treat the $10.80–$11.30 non-GAAP guide with that caveat.
• Goodwill at $3.04B vs total equity $2.95B — goodwill now exceeds book equity. A serial acquirer carrying goodwill > equity is one bad-impairment-cycle from negative tangible equity. Watch.
• Leverage step-up: net debt ~$2.49B, revolver at $1.16B; debt funded simultaneously with buybacks. Manageable against ~$700M+ run-rate non-GAAP earnings, but it removes balance-sheet slack right as a regulatory threat builds.
• Cash trapped offshore: $190.4M of $191.8M cash is in non-US entities (only $1.4M in the US) — US capital return is debt-/repatriation-funded.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: none. regulatory/regulatory-findings.md (EDGAR EFTS LR + AAER, 2021-06-30 → 2026-06-30) returned 0 SEC findings.
• Securities & derivative litigation (10-Q Item 1 / Commitments note): a putative securities class action (filed May 19, 2023, D. Mass.) alleges CRL's disclosures about non-human-primate importation during May 5, 2020 – Feb 21, 2023 were materially false/misleading; defendants are CRL, CEO James Foster, and former CFO David Smith. The district court dismissed it (Jul 1, 2024), but the First Circuit reversed in part on Aug 15, 2025, sending the securities-fraud claims back to district court; lead plaintiff is being substituted to Oklahoma Firefighters Pension. Two derivative suits (Nov 8, 2023; Aug 2, 2024) make parallel fiduciary-duty claims. CRL "cannot reasonably estimate the maximum potential exposure or range of possible loss". This is a live, recently-escalated overhang — not resolved.
• Non-SEC enforcement (NHP / DOJ): the underlying matter is the well-documented US DOJ / Fish & Wildlife investigation into Cambodian cynomolgus macaque imports (smuggling of wild-caught animals labelled purpose-bred), which forced CRL to voluntarily suspend Cambodian NHP shipments in 2023 and is the root of the litigation. The Jan-2026 K.F. Cambodia acquisition + "enhanced procedures to ensure purpose-bred" sourcing is the operational remediation.
• Verdict: No SEC accounting-fraud findings, but a material, active securities class action (now revived on appeal) and a federal NHP-sourcing investigation are real legal/headline risks — verified via SEC EDGAR EFTS (LR, AAER, nil), 10-Q Item 1 / Commitments note, and web as of 2026-06-30.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (non-GAAP EPS, FY2026–FY2028)

Built bottom-up from management's own FY2026 guide and the segment trajectory. FY2026 base anchors to the reaffirmed guide; FY2027–28 are ``.

• FY2026 (base): non-GAAP EPS ~$11.05 — midpoint of the reaffirmed $10.80–$11.30 guide (+5–10% over the implied FY2025 ~$10.28). Drivers: organic revenue −0.5% to −1.5%, +120–150 bps margin expansion (restructuring savings + amortisation roll-off), continued buyback shrinking the ~48.2M share count.
• FY2027 (base): ~$11.9. Bull ~$12.8 (DSA re-accelerates to mid-single-digits on biotech-funding recovery + book-to-bill >1; faster buyback). Bear ~$10.3 (FDA NAMs guidance bites NHP study volumes; DSA flat-to-down; margin expansion stalls on rising corporate cost).
• FY2028 (base): ~$12.9. Bull ~$14.5 / Bear ~$10.0 (the bear path is where the NHP-disruption thesis compounds against DSA mix).

Every input labelled; all outputs ``. The honest base case is high-single-digit EPS growth off a flat-to-declining revenue line — a margin-and-buyback story, not organic growth. Per --watchlist rules, no forecast.ts create logged.

Lens 12 · Bull vs Bear

Bull case. CRL is the irreplaceable preclinical backbone of drug R&D at a cyclical trough that is visibly flattening (Q1 DSA +0.7%, Manufacturing +6.8%). The biotech-funding winter is thawing; book-to-bill recovers; the FY2025 impairments are behind it, so GAAP and non-GAAP converge and earnings quality improves from here. Under Elliott, capital allocation flipped to discipline + a $1.0B buyback, and a long-time operator (Girshick) is running it for margin. The K.F. Cambodia deal secures a scarce input and removes the NHP-supply tail. Endosafe and Manufacturing are quietly compounding. At ~18x forward / ~11.4x EBITDA you are paying a market multiple for a wide-moat franchise with self-help margin levers and a shrinking share count — a classic activist-driven re-rating with optionality on a strategic-review outcome (portfolio reshaping / asset sales).

Bear case (permanent-impairment risks).

1. The FDA NAMs roadmap structurally erodes DSA. The April-2025 roadmap, with Year-1 goals "met" (April 2026) and draft guidance specifically aimed at eliminating NHP testing for monoclonal antibodies, attacks the highest-margin part of CRL's biggest segment. CRL just sank $507M into NHP supply as the regulator signals it wants to phase out the demand for it — the moat and the obsolescence are the same asset.
2. Structural, not just cyclical, revenue decline. Two straight years down; large pharma is insourcing and rationalising R&D; pricing power is eroding. If this is secular, the "trough" never re-accelerates.
3. Goodwill > equity + levered balance sheet leave little room for another impairment or a demand air-pocket while buying back stock on a drawn revolver.

Pre-mortem (18 months out, thesis broke): FDA mAb-NAMs guidance finalises and large-molecule sponsors quietly reroute safety packages to in-vitro/computational vendors; DSA bookings roll over again; the K.F. Cambodia asset is written down; the buyback masked deteriorating organics until guidance is cut; the multiple de-rates to ~13x as the market reprices CRL from "quality compounder" to "melting ice cube with good cash flow."

Are multiples too high? ~18x forward is not demanding versus clinical-CRO peers, but it is not cheap for a company with a declining top line and a regulator targeting its profit centre. The valuation prices stabilisation, not re-acceleration, and gives little discount for the NAMs tail.

Contrarian view (what the market refuses to see): the bull narrative treats NHP-supply security (K.F. Cambodia) as a moat; the contrarian read is that CRL is heavily capitalising the exact modality the FDA is engineering out, and that the real long-term winner inside CRL is the non-animal franchise (AMAP / in-vitro / Endosafe / the Lilly-TuneLab AI rails), which is small today and not what investors are paying ~$10B for. The market is buying the monkeys; the value is in the test tubes.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• Revenue concentration shift: revenue is concentrated in DSA (~60%), and within DSA in NHP-dependent large-molecule safety studies — precisely the slice the FDA's mAb-NAMs guidance targets. A modest reroute of biologics safety work to alternative methods hits the most profitable revenue first.
• The moat is weaker than bulls think: GLP-tox stickiness is real while studies are required by regulation; the entire bull case for the moat is regulatory mandate, and the regulator is the one moving against it. That is the worst possible source of a moat to bet on.
• Most dangerous competitor bulls underestimate: not another CRO — it's NAMs/organ-on-chip and in-silico tox vendors + big-pharma internal labs adopting them, blessed by FDA. CRL's own AMAP admits the direction of travel.
• Worst capital-allocation moves: a decade of debt-funded M&A now visible as goodwill > equity and serial impairments ($210M FY2025); then $507M on a Cambodian NHP supplier whose product the FDA wants to phase out, funded on the revolver while buying back $200M+ of stock per quarter. The securities class action over NHP disclosures (revived by the First Circuit) names the CEO and two former CFOs.
• What must hold for ~$213: that the DSA decline is purely cyclical (not secular), that NAMs adoption is a decade away, that margin expansion (120–150 bps) lands, and that the buyback keeps shrinking the count. If organic growth disappoints 20–30%, DSA operating margin (high fixed cost) gears down hard, the margin-expansion guide breaks, non-GAAP EPS slips toward the ~$10 bear, and an ~18x multiple compresses toward ~12–13x → a stock in the $120–$150s, i.e. back to the 52-week low.
• Single scenario that permanently impairs: the FDA mAb-NAMs guidance finalises and is rapidly adopted by biologics sponsors over 2026–2028, structurally shrinking NHP safety-study TAM faster than CRL's NAMs franchise can backfill — a slow, permanent de-rating of the core, with the K.F. Cambodia asset stranded. Plausibility: moderate and rising — directionally certain, uncertain on timing.

Lens 14 · Management Questions (ordered by information value)

1. The FDA's mAb-NAMs draft guidance targets the elimination of NHP testing for monoclonal antibodies — what % of DSA revenue is NHP-dependent large-molecule safety work, and what is your honest TAM trajectory for that slice over 5–10 years?
2. You spent $507M on K.F. Cambodia to secure NHP supply in the same window the FDA is phasing out NHP demand — walk us through the return assumptions and the impairment risk on that asset under an accelerated-NAMs scenario.
3. Is the two-year revenue decline cyclical or secular? What specific leading indicators (net book-to-bill, proposal volume, RFP win-rate, study cancellations) tell you the DSA trough is behind you?
4. What is the current DSA net book-to-bill, and how has it trended over the last six quarters?
5. The $10.80–$11.30 non-GAAP guide implies 120–150 bps of margin expansion — bridge it for us (restructuring savings vs amortisation roll-off vs mix), and what breaks it?
6. Unallocated corporate cost rose to $80.6M in Q1 (from $54.3M) — what is driving that, and is it permanent?
7. How big is the non-animal / NAMs franchise (AMAP, in-vitro, in-silico) as a share of revenue today, and at what growth rate — can it offset NHP-study erosion this decade?
8. Goodwill ($3.04B) now exceeds total equity ($2.95B) after serial impairments — what is your impairment-test sensitivity, and where is the next risk?
9. You drew the revolver to $1.16B to fund M&A while repurchasing $208M of stock in the quarter — what is your target net-leverage ceiling, and how do you prioritise buyback vs deleveraging vs M&A from here?
10. What is the realistic range of outcomes and timeline on the revived securities class action (First Circuit reversal) and the two derivative suits, and what reserve, if any, have you taken?
11. The strategic review under the Elliott Cooperation Agreement — what is genuinely on the table (portfolio reshaping, divestitures, a sale), and what is the decision timeline?
12. Operating cash flow fell to $41M on a $106M working-capital build — how much is K.F. Cambodia consolidation noise vs underlying inventory/receivables deterioration, and where does FY2026 OCF land?
13. With Foster transitioning out after 50 years, what changes under Girshick that wouldn't have happened otherwise — concretely?
14. How is the Lilly TuneLab / AI-discovery partnership structured economically, and is "safety-testing layer under the AI platforms" a real growth vector or a defensive option?
15. Almost all cash is offshore ($1.4M of $191.8M in the US) — how do you fund US capital return durably without leaning on the revolver?

---